Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(17):1377-1378; doi:10.1093/jnci/92.17.1377
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 17, 1377-1378, September 6, 2000
© 2000 Oxford University Press

NEWS

Lines Disintegrating Between Industry, Academic Research

Steve Benowitz

Potential conflicts of interest among academic scientists funded by the pharmaceutical industry are hardly new. As industry increasingly supports basic research and clinical trials—perhaps as much as 70% of clinical trial funding in this country comes from industry (and not the National Institutes of Health, the traditional source)—opportunities for potential conflicts will only grow.

Yet the question remains, how much of a problem is conflict of interest? Does a cozy relationship between academic researcher X and company Y, with the researcher’s laboratory virtually dependent on company support to conduct its research on a potential anticancer agent, for example, compromise the ability to do objective research? Will the scientist be just a bit more likely . . . [Full Text of this Article]

Industry–Academe Collaborations

Potential Conflicts Abound


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?